Article

FDA Approves First OTC Acetaminophen-Ibuprofen Combination

Author(s):

The GSK-branded Advil will be available as a dual-action pain reliever later this year.

FDA, ibuprofen, acetominophen, advil

The US Food and Drug Administration (FDA) has approved the first dual-action over-the-counter (OTC) combination of ibuprofen and acetaminophen in the US.

GlaxoSmithKline’s (GSK) Advil Dual Action with Acetaminophen was approved as an OTC pain relief combination therapy Friday, supported by data from 7 clinical trials. In 3 such trials, the drug showed pivotal efficacy and safety outcomes in assessment for patient pain relief.

The clinical trial data, according to GSK, supports the pain relief indication, and demonstrates superior efficacy of fixed-dose combination ibuprofen plus acetaminophen when compared to lone 250 mg ibuprofen or 500 mg acetaminophen, when assessing for improvements in acute pain symptoms across multiple pre-specified endpoints.

Ibuprofen is a nonsteroidal anti-inflammatory drug that temporarily reduces the production of prostaglandins, which are responsible for signaling for swelling and pain. Acetaminophen is a pain reliever shown to block the transmission of pain signals to the brain.

Franck Riot, head of R&D for GSK Consumer Healthcare, noted the 2 individual therapies have been used by consumers for decades for widely varying instances of pain: headaches, muscle aches, backaches, arthritis, and other joint pain.

“Now Advil, the No. 1 selling OTC pain reliever, will offer US consumers the first-ever alternative option—a single, fixed-dose combination pain reliever,” Riot said in a statement. “As the world-leader in pain relief, Advil Dual Action and our recently FDA-approved Voltaren Arthritis Pain gel, demonstrates GSK's commitment to providing new safe, effective and convenient pain relief options for consumers."

GSK announced the combination therapy will be available as an OTC option nationwide this year.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.